LATITUDE Pharmaceuticals
  • Home
  • The LATITUDE Team
  • Formulation Expertise and Specialties
  • Services and Capabilities
    • Preformulation
    • Formulation
    • Deformulation
    • Analytical Methods
    • Equipment List
  • Drug Delivery Systems & Formulation Platforms
  • Licensing Opportunities
  • R&D and Pilot Scale Manufacturing
  • Case Studies
  • GMP Manufacture and Testing
  • News/Press Releases
  • Employment
  • Contact
Select Page

Licensing Opportunities

LATITUDE’s internal product development activities focus on addressing areas of unmet medical need through formulation. These efforts include taking known drugs and making significantly safer, more stable and/or easier-to-use versions that also comprise new intellectual property.  Such re-formulations are designed to be eligible for the fast-track 505(b)(2) NDA, offering considerable time and cost savings for the licensor during FDA approval. LATITUDE’s currently available 505(b)(2) product candidates include:

Intra-V : a stable liquid, ready-to-use (RTU) intravenous formulation of the antibiotic vancomycin

Opti-V : a stable, liquid RTU, ophthalmic formulation of the antibiotic vancomycin

PumpaGon : a stable aqueous glucagon formulation suitable for a bihormonal insulin pump or artificial pancreas for prevention and treatment of hypoglycemia

PAC-E : a safer formulation of the anti-cancer drug paclitaxel (TAXOL®, ABRAXANE®) that shows significantly-reduced peripheral neuropathy, and which can be tolerated at a much higher dose than TAXOL®.

Nano-K : a stable, liquid, Cremophor®-free vitamin K formulation for preventing coagulation deficiencies in newborns or for treatment of dysmenorrhea (replacement for AquaMEPHYTON®).

Nano-A : a stable, polysorbate-free RTU amiodarone nanoemulsion for treating cardiac arrhythmias (replacement for Nexterone®)

24H Tramadol : a 24 hr release tablet for tramadol with proven in vitro release profile equivalent to Ultram® and Ryzolt®.

LATITUDE has also applied its formulation expertise to develop novel formulations of known drugs in new dosage formats:

  • Diazepam (benzodiazepine for seizure rescue) for subcutaneous/intramuscular injection
  • Celecoxib (NSAID COX-2 inhibitor) for intravenous injection
  • Diclofenac (NSAID) for intravenous injection
  • Insulin in an extended-release depot
  • Progesterone for intravenous injection

For further information on these Licensing Opportunities, click here.

  • Facebook
  • Google
  • RSS

Designed by Oliver Web Guy LLC | Powered by WordPress